Sanofi Return on Investment 2012-2025 | SNY
Current and historical return on investment (ROI) values for Sanofi (SNY) over the last 10 years.
| Sanofi ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2025-09-30 | $9.76B | $99.63B | 10.21% |
| 2025-06-30 | $9.64B | $94.77B | 13.65% |
| 2025-03-31 | $9.13B | $90.80B | 13.05% |
| 2024-12-31 | $8.22B | $97.01B | 17.39% |
| 2024-09-30 | $8.54B | 18.17% | |
| 2024-06-30 | $7.84B | $92.08B | 16.67% |
| 2024-03-31 | $8.45B | 17.69% | |
| 2023-12-31 | $9.59B | $96.00B | 20.08% |
| 2023-09-30 | $10.30B | 21.70% | |
| 2023-06-30 | $11.11B | $95.07B | 23.40% |
| 2023-03-31 | $10.71B | 22.82% | |
| 2022-12-31 | $10.72B | $94.83B | 22.85% |
| 2022-09-30 | $12.21B | 52.62% | |
| 2022-03-31 | $8.80B | 35.93% | |
| 2021-09-30 | $9.03B | 36.89% | |
| 2021-03-31 | $10.31B | 0.00% | |
| 2020-09-30 | $9.32B | 0.00% | |
| 2020-03-31 | $7.94B | 0.00% | |
| 2019-09-30 | $6.79B | 33.11% | |
| 2019-03-31 | $6.71B | 32.71% | |
| 2018-03-31 | $6.77B | 16.67% | |
| 2017-12-31 | $7.07B | $82.04B | 17.42% |
| 2017-09-30 | $7.72B | 18.98% | |
| 2017-06-30 | $8.01B | $80.29B | 19.69% |
| 2017-03-31 | $8.14B | 20.27% | |
| 2016-12-31 | $7.59B | $82.49B | 18.91% |
| 2016-09-30 | $8.06B | 41.24% | |
| 2016-06-30 | $7.47B | $78.17B | 19.54% |
| 2016-03-31 | $7.72B | 19.35% | |
| 2015-09-30 | $7.96B | 12.90% | |
| 2015-06-30 | $7.84B | $74.72B | 9.42% |
| 2014-06-30 | $8.29B | $84.89B | 12.86% |
| 2013-06-30 | $8.36B | $87.34B | 12.43% |
| 2012-06-30 | $9.00B | $85.62B | 19.82% |
| 2012-03-31 | $8.41B | 17.63% | |
| 2011-12-31 | $8.89B | $95.95B | 18.64% |
| 2011-09-30 | $8.20B | 18.80% | |
| 2011-06-30 | $8.97B | $94.81B | 20.57% |
| 2011-03-31 | $10.32B | 26.49% | |
| 2010-12-31 | $9.22B | $79.65B | 23.67% |
| 2010-09-30 | $8.91B | 23.46% | |
| 2010-06-30 | $8.83B | $76.10B | 23.25% |
| 2010-03-31 | $8.80B | 24.05% | |
| 2009-12-31 | $8.81B | $75.88B | 24.08% |
| 2009-09-30 | $9.40B | 26.30% | |
| 2009-06-30 | $8.62B | $70.51B | 24.12% |
| 2009-03-31 | $7.71B | 21.42% | |
| 2008-12-31 | $7.99B | $72.45B | 22.20% |
| 2008-09-30 | $7.86B | 22.79% | |
| 2008-06-30 | $8.22B | $71.52B | 23.83% |
| 2008-03-31 | $7.78B | 23.19% | |
| 2007-12-31 | $7.93B | $66.42B | 23.62% |
| 2007-09-30 | $7.81B | 23.85% | |
| 2007-06-30 | $7.00B | $67.81B | 21.36% |
| 2007-03-31 | $6.85B | 22.01% | |
| 2006-12-31 | $5.85B | $63.21B | 18.78% |
| 2006-09-30 | $3.94B | 12.55% | |
| 2006-06-30 | $5.16B | $61.37B | 16.43% |
| 2006-03-31 | $4.82B | 14.89% | |
| 2005-12-31 | $4.48B | $64.23B | 13.85% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $112.219B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |